"None of these headwinds can be faced without us bending. From my perspective, this move is a response to those changes, and it demonstrates our ability to be able to meet a challenge - it is important because it is going to continue," he told BioPharmaDispatch.
Dennis Bastas on Arrotex and creating the largest company by volume in PBS history
July 11, 2019 Latest NewsBioPharmaDispatch ExecutiveNews of the Day
Latest Video
New Stories
-
'Patients can’t wait – swift action and access are the only possible moves from here'
August 26, 2025 - - Latest News -
Vaxxas secures $90 million in funding to commercialise needle-free vaccination delivery technology
August 25, 2025 - - Australian Biotech -
Bayer partners with Arrotex to strengthen access to oral contraceptives
August 25, 2025 - - Latest News -
The next negotiation was always going to be complicated, the new reality will make it more so
August 25, 2025 - - Latest News -
UK industry cites US pricing ambitions in collapse of new agreement negotiation
August 25, 2025 - - Latest News -
Botanix appoints Dr Patricia Walker as a non-executive director
August 25, 2025 - - Australian Biotech -
First site initiated for Neuren’s Phelan-McDermid syndrome Phase 3 trial
August 25, 2025 - - Australian Biotech